ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
111.22
-0.51 (-0.46%)
As of 3:12PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close111.73
Open111.89
Bid111.27 x 800
Ask111.33 x 900
Day's Range110.89 - 113.99
52 Week Range92.56 - 140.77
Volume1,337,610
Avg. Volume1,706,769
Market Cap24.813B
Beta (3Y Monthly)1.45
PE Ratio (TTM)162.36
EPS (TTM)0.69
Earnings DateFeb 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est164.35
Trade prices are not sourced from all markets
  • Markityesterday

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    # Alexion Pharmaceuticals Inc ### NASDAQ/NGS:ALXN View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $11.23 billion over the last one-month into ETFs that hold ALXN are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • InvestorPlace5 days ago

    Why Sarepta Therapeutics Stock Is Starting to Shine Again

    Sarepta Therapeutics (NASDAQ:SRPT) started 2019 with very high volatility. After spiking to around $125 a share on Jan. 7, SRPT stock gave up those gains when markets took in the developments in its DMD pipelines and its Exondys 51 fourth-quarter sales outlook. Although shares rebounded from December 2018 lows, should biotech stock investors seriously consider investing in this company? At the J.P. Morgan conference, Sarepta said it will run 45 biopsies this quarter for SRP-4045. This is an investigational compound that treats DMD or Duchenne muscular dystrophy patients with mutations in the DMD gene. The drug works by directing cells, through Sarepta's PMO, to skip exon 45 when processing RNA. The dystrophin protein is shortened but is still synthesized, slowing the negative symptoms of DMD. If the biopsies are positive, Sarepta will file a marketing application, setting up a possible approval date of early 2020. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### SRPT's Sales Outlook SRPT stock volatility rose after the company issued its revenue outlook for Exondys 51. In the fourth quarter ended Dec. 31, 2018, it made $84.4 million in revenue from sales of Exondys 51. For 2018, revenue was around $301 million. It ended that same period with a healthy balance of $1.1 billion in cash. * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors Markets reacted negatively to the outlook because it expected quarterly revenue of $85.8 million. The barely $2 million difference is a rounding error and the market quickly realized it. Quarterly revenue is in line with forecasts. As markets rebounded, taking the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) up 11.5% on the week, SRPT stock also rose the same amount (11%). Sarepta's global growth plans should lower the risks of relying solely in one market: "We continue to build our international presence with limited infrastructure but dedicated colleagues in Latin America and Europe and a managed access program or MAP now live in some 44 countries. We should continue to see modest contribution from our MAP throughout 2018 with increasing contribution in 2019 and beyond." Source: SA Transcript ### Impressive Talent at Sarepta Sarepta highlighted the 25 programs in RNA and gene therapy underway. Its staff talent consists of over 500 professionals. This leading gene therapy team could deliver on bringing 3 RNA-therapies by 2020. It may potentially treat 30% of the DMD market. Historically, the team is showing that it is delivering. FY 2018 revenue nearly doubled to $301 million, up from the 2017 revenue of $154.6 million. ### Investing Opportunity Sarepta is a top five rare disease company by market cap. Only Alexion Pharmaceuticals (NASDAQ:ALXN), BioMarin Pharmaceutical (NASDAQ:BMRN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are bigger. SRPT stock is underperforming compared to its peers. While the other firms' stock price traded closer to its 52-week highs after the market rally in the last few days, Sarepta is still around 33% below its yearly high. Wall Street coverage gained steam in the last few days. The company received over five "buy" calls, with a price target ranging from $161 to as high as $267. Analyst Firm Position Price Target Date Debjit Chattopadhyay H.C. Wainwright Buy $267.00 yesterday Salveen Richter Goldman Sachs Buy $191.00 2 days ago Matthew Harrison Morgan Stanley Buy $161.00 2 days ago Brian Skorney Robert W. Baird Buy $202.00 2 days ago Alethia Young Cantor Fitzgerald Buy $217.00 2 days ago Yun Zhong Janney Montgomery Buy $200.00 2 days ago Brian Abrahams RBC Capital Buy -- 3 days ago Martin Auster Credit Suisse Buy $189.00 3 days ago Tim Chiang BTIG Buy $190.00 13 days ago Source: tipranks ### Investment Suitability Like with all biotech companies in the discovery phase, SRPT is volatile and risky. Any FDA approval delays could disappoint markets, sending the stock lower. Clinical study costs could rise, but in Sarepta's case, the company has plenty of cash on hand. It is unlikely to need a cash raise through a share sale. * 7 Stocks to Buy That Are Run By Billionaires ### Bottom Line on SRPT Stock Sarepta Therapeutics stock benefited from the latest rebound in biotechnology stocks, but could move even higher in the longer term. It has a goal of commencing its confirmatory trial with commercial material this year. Given the strong team, doctors and scientists involved, chances are good that the trial, which has 24 patients, goes well and will bring positive results. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Why Sarepta Therapeutics Stock Is Starting to Shine Again appeared first on InvestorPlace.

  • Estimating The Fair Value Of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
    Simply Wall St.5 days ago

    Estimating The Fair Value Of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

    Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) as an investment opportunity by taking the Read More...

  • Three tech, three biotech companies that are top takeover targets in 2019
    MarketWatch6 days ago

    Three tech, three biotech companies that are top takeover targets in 2019

    Bristol-Myers Squibb (BMY) last week ponied up $74 billion, a 54% premium, for biotechnology heavyweight Celgene. Big Pharma needs the next generation of treatments to fuel future growth. Another massive purchase was IBM’s (IBM) $33 billion takeover of software firm Red Hat Inc. (RHT) The fact that Big Blue paid a premium of more than 60% in October, one of the worst months for stocks in recent memory, is proof that mega-cap technology companies aren’t afraid to shell out big bucks even amid talk of a tough stock market.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    # Alexion Pharmaceuticals Inc ### NASDAQ/NGS:ALXN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding ALXN are favorable, with net inflows of $17.04 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of ALXN earnings conference call or presentation 24-Oct-18 12:00pm GMT

    Q3 2018 Alexion Pharmaceuticals Inc Earnings Call

  • Why Alexion Pharmaceuticals Stock Fell 21% in December
    Motley Fool8 days ago

    Why Alexion Pharmaceuticals Stock Fell 21% in December

    The drugmaker got caught up in spiking market volatility last month.

  • 4 Biotechs That Are Potential Buyouts Post Celgene Deal
    Zacks8 days ago

    4 Biotechs That Are Potential Buyouts Post Celgene Deal

    We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    # Alexion Pharmaceuticals Inc ### NASDAQ/NGS:ALXN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding ALXN are favorable, with net inflows of $17.04 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire9 days ago

    Alexion to Report Fourth Quarter and Full Year 2018 Results on Monday, February 4, 2019

    Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2018 before the US financial markets open on February 4, 2019.

  • Business Wire14 days ago

    Alexion to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Alexion Pharmaceuticals today announced that management will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8, 2019 at 7:30 a.m., PT.

  • Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
    Zacks20 days ago

    Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure

    Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.

  • Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
    Zacks23 days ago

    Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder

    Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.

  • Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
    Zacks23 days ago

    Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija

    Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit25 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Business Wire26 days ago

    Alexion to Present at the Goldman Sachs 11th Annual Healthcare CEO Conference

    Alexion Pharmaceuticals today announced that management will present at the Goldman Sachs 11th Annual Healthcare CEO Conference in New York, NY on Thursday, January 3, 2019 at 8 a.m., ET.

  • 'Santa Comes Early' As This Biotech Stock Grabs Its Fourth Approval
    Investor's Business Daily26 days ago

    'Santa Comes Early' As This Biotech Stock Grabs Its Fourth Approval

    Christmas came early for Alexion stock on Friday after the FDA approved its treatment for a rare blood disease. Ultomiris is a next-generation version of Soliris, Alexion's biggest drug.

  • Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Business Wire26 days ago

    Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Alexion Pharmaceuticals, Inc. (ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved ULTOMIRIS™ (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating ultra-rare blood disorder characterized by complement-mediated destruction of the red blood cells (hemolysis). The approval of ULTOMIRIS comes ahead of the Prescription Drug User Fee Act (PDUFA) date of February 18, 2019, set by the FDA as part of an expedited eight month review following Alexion’s use of a rare disease priority review voucher.

  • Reuters26 days ago

    U.S. FDA approves Alexion Pharma's rare blood disorder drug

    The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, nearly two months earlier than expected. The drug's sales are expected to reach ...

  • Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead
    Zacks26 days ago

    Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead

    Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.

  • Allakos (ALLK) Catches Eye: Stock Jumps 6.5%
    Zacks26 days ago

    Allakos (ALLK) Catches Eye: Stock Jumps 6.5%

    Allakos (ALLK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Alexion Pharmaceuticals Enters Oversold Territory
    Zacks27 days ago

    Alexion Pharmaceuticals Enters Oversold Territory

    Alexion Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint
    Zacks28 days ago

    Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint

    Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.

  • Achillion Reports Positive Interim Data on Factor D Inhibitors
    Zacks29 days ago

    Achillion Reports Positive Interim Data on Factor D Inhibitors

    Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.